Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 12, 2013, Pages

  Feng, Mingqian ^a   Gao, Wei ^a   Wang, Ruoqi ^a   Chen, Weizao ^b   Man, Yan Gao ^c   Figg, William Douglas ^a   Wang, Xin Wei ^a   Dimitrov, Dimiter S ^b   Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Cell growth; Heparan sulfate proteoglycans; Liver cancer; Monoclonal antibodies; Phage display

Indexed keywords

ANTINEOPLASTIC AGENT; EPITOPE; GLYPICAN 3; HN3 ANTIBODY; NANOBODY; PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA CONCENTRATION-TIME CURVE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; G1 PHASE CELL CYCLE CHECKPOINTS; GLYPICANS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; SINGLE-CHAIN ANTIBODIES; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875256696     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217868110     Document Type: Article

References (43)

1. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127(5, Suppl 1)S5-S16.
2. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-2576.
3. Cao H, Phan H, Yang LX (2012) Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32(4):1379-1386.
4. Filmus J, Selleck SB (2001) Glypicans: Proteoglycans with a surprise. J Clin Invest 108(4): 497-501.
5. Ho M, Kim H (2011) Glypican-3: A new target for cancer immunotherapy. Eur J Cancer 47(3):333-338.
6. Kim MS, Saunders AM, Hamaoka BY, Beachy PA, Leahy DJ (2011) Structure of the protein core of the glypican Dally-like and localization of a region important for hedgehog signaling. Proc Natl Acad Sci USA 108(32):13112-13117.
7. Svensson G, Awad W, Håkansson M, Mani K, Logan DT (2012) Crystal structure of N-glycosylated human glypican-1 core protein: Structure of two loops evolutionarily conserved in vertebrate glypican-1. J Biol Chem 287(17):14040-14051.
8. Baumhoer D, et al. (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129(6):899-906.
9. Llovet JM, et al. (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131(6):1758-1767.
10. Zhu ZW, et al. (2001) Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48(4):558-564.
11. Pilia G, et al. (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi- Behmel overgrowth syndrome. Nat Genet 12(3):241-247.
12. Cano-Gauci DF, et al. (1999) Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 146(1):255-264.
13. Liu B, et al. (2010) Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice. Hepatology 52(3):1060-1067.
14. Zittermann SI, Capurro MI, Shi W, Filmus J (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126(6): 1291-1301.
15. Feng M, Kim H, Phung Y, Ho M (2011) Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 128(9):2246-2247.
16. Sun CK, Chua MS, He J, So SK (2011) Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia 13(8): 735-747.
17. Lee KP, et al. (2010) The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 107(18): 8248-8253.
18. Lu L, et al. (2010) Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 107(4):1437-1442.
19. Zhou D, et al. (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16(5):425-438.
20. Midorikawa Y, et al. (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103(4):455-465.
21. Capurro M, et al. (2003) Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89-97.
22. Hippo Y, et al. (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64(7): 2418-2423.
23. Yamauchi N, et al. (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18(12):1591-1598.
24. Phung Y, Gao W, Man YG, Nagata S, Ho M (2012) High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs 4(5):592-599.
25. Ishiguro T, et al. (2008) Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68(23):9832-9838.
26. Nakano K, et al. (2010) Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 21(10):907-916.
27. Nakano K, et al. (2009) Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 378(2):279-284.
28. Henderson KA, et al. (2007) Structure of an IgNAR-AMA1 complex: Targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure 15(11): 1452-1466.
29. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126-1136.
30. Stijlemans B, et al. (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279(2):1256-1261.
31. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS (2008) Construction of a large phagedisplayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 382(3):779-789.
32. Stork R, et al. (2008) N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 283(12):7804-7812.
33. Basu S, Totty NF, Irwin MS, Sudol M, Downward J (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11(1):11-23.
34. Kilili GK, Kyriakis JM (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem 285(20):15076-15087.
35. Kim D, et al. (2010) Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS ONE 5(3):e9616.
36. O'Neill E, Kolch W (2005) Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 4(3):365-367.
37. Romano D, et al. (2010) Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res 70(3):1195-1203.
38. Mizuno T, et al. (2012) YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 31(1):1-6.
39. Chen W, et al. (2012) NSC 74859-mediated inhibition of STAT3 enhances the antiproliferative activity of cetuximab in hepatocellular carcinoma. Liver Int 32(1):70-77.
40. Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H (2005) EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70(11):1568-1578.
41. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282(5739): 615-616.
42. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42(9):3858-3863.
43. Kaneko O, et al. (2009) A binding domain on mesothelin for CA125/MUC16. J Biol Chem 284(6):3739-3749.